Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesEndocrinologyZing Health CGM Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy N/A

    Continuous Glucose Monitors (CGM) & Diabetic Testing Supplies Coverage 2025

    Customize your policy alerts

    Sign up for all zing_health policy alerts

    Know when zing_health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Zing Health coverage, prior authorization, preferred products, and member cost sharing for continuous glucose monitors, diabetic testing supplies, and specified insulin delivery devices for members with diabetes, prediabetes, gestational diabetes, or certain medication-related blood glucose risks.

    Policy Summary
    PayerZing Health
    PolicyContinuous Glucose Monitors (CGM) & Diabetic Testing Supplies Coverage 2025
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionRequest CGM authorization from Zing and submit the required clinical documentation and prescription.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    $0Preferred diabetic supplies cost share
    20%Non-preferred diabetic supplies coinsurance
    $0Preferred CGM cost share
    20%Non-preferred CGM coinsurance
    12 months
    Policy Summary
    PayerZing Health
    PolicyContinuous Glucose Monitors (CGM) & Diabetic Testing Supplies Coverage 2025
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionRequest CGM authorization from Zing and submit the required clinical documentation and prescription.
    SourceLink
    On This Page
    Continuous Glucose Monitor Coverage CriteriaAuthorization and Documentation RequirementsContinuous Glucose Monitoring OverviewMonitoring Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CGM authorization period
    2Preferred CGM models

    Continuous Glucose Monitor Coverage Criteria

    CGM prior authorization approval criteria

    CGMs will be approved when all of the following are met.

    CGM approval requirements

    • Qualifying condition

      • Diabetes: The patient has diabetes.
      • Prediabetes: The patient has prediabetes.
      • Gestational diabetes: The patient has gestational diabetes.
      • Concomitant medication: The patient is being treated with a concomitant drug that may affect blood sugar levels.
    • Treatment or clinical documentation pathway

      • Insulin therapy: The patient is being treated with any insulin therapy.
      • Prescriber clinical rationale: The prescriber provides documentation indicating that the patient's blood sugar levels will have improved control using a continuous glucose monitor as a substitute for traditional diabetes testing supplies.

    Clinical CGM coverage requirements

    A CGM will be covered when all of the following criteria are met.

    Clinical coverage requirements

    • Qualifying diagnosis: The member has a diagnosis of diabetes, prediabetes, or gestational diabetes.

      At least one diagnosis is required.

    • Insulin treatment: The member is treated with any insulin therapy.
    • Prescriber documentation: The prescriber documents that the member's blood sugar levels are more appropriate to control with the monitoring approach described in the policy than with a traditional monitor and supplies.

    Authorization and Documentation Requirements

    Prior Authorization

    Request CGM prior authorization

    The doctor must request CGM authorization from Zing and submit the required clinical documentation and prescription. When all stated criteria are met, CGM approval is issued for 12 months.

    Documentation Required

    Include required authorization documentation

    Submit documentation showing that the member meets CGM coverage requirements, a prescription for the CGM and its supplies, and documentation explaining that the member’s diabetes is managed by the prescribing doctor at least every 6 months.

    • Documentation showing the member meets CGM coverage requirements
    • Prescription for the CGM and its supplies
    • Documentation that the member’s diabetes is managed by the prescribing doctor at least every 6 months

    Continuous Glucose Monitoring Overview

    A continuous glucose monitor (CGM) is a wearable device placed beneath the skin that provides blood sugar readings continuously throughout the day. Unlike traditional diabetes monitoring, which measures glucose only when the member performs a fingerstick test, a CGM provides ongoing glucose information to support blood sugar management.

    Monitoring Terms

    Continuous glucose monitor (CGM)
    DeviceA wearable device placed underneath the skin.
    MeasurementProvides blood sugar levels continuously throughout the day.
    Traditional diabetes monitor
    Testing methodMeasures blood sugar only when the member tests using a fingerstick.
    Monitoring typeTraditional diabetes monitoring, unlike CGM, does not provide continuous blood sugar readings.
    Documentation Required

    Document the clinical rationale

    The prescriber must document the member’s blood sugar levels and why management is more appropriate with the requested monitoring approach. The documentation must address improved blood sugar control using a CGM as a substitute for traditional diabetes testing supplies.

    Denial Risk

    Avoid denial for unmet CGM criteria

    CGM authorization will not be approved unless the patient meets one qualifying condition and one qualifying treatment or clinical documentation pathway. The submission must show diabetes, prediabetes, gestational diabetes, or treatment with a concomitant drug that may affect blood sugar levels, plus either any insulin therapy or the required prescriber documentation supporting CGM use.

    • Qualifying condition: diabetes, prediabetes, gestational diabetes, or treatment with a concomitant drug that may affect blood sugar levels
    • Qualifying pathway: any insulin therapy or prescriber documentation that CGM will improve blood glucose control as a substitute for traditional diabetes testing supplies